Mr. Andrew Kiguel reports

REALBOTIX PROVIDES UPDATE ON NASDAQ LISTING

Realbotix Corp. has provided an update on its previously announced transaction to list Realbotix LLC, a wholly owned subsidiary of Realbotix, on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix Inc. (Nasdaq: ONCO).

The proposed transaction will result in the robotics and AI business of RealLLC to be listed on Nasdaq, with the parent company (Realbotix) maintaining a 75- to 90-per-cent ownership stake. No action is required by existing Realbotix shareholders as there are no changes to the structure of the parent company. The transaction is expected to close by October, 2026.

Benefits to Realbotix shareholders:

• Realbotix shareholders retain the upside potential of the enterprise robotics and AI (artificial intelligence) business within RealLLC.
• There are no shares being issued by the parent company nor is a share consolidation required in the proposed transaction.
• Realbotix will appoint four out of five directors to the ONCO board of directors at close.
• This transaction unlocks value in the commercial robotics and AI business held at RealLLC by separating it from the parent company's direct-to-consumer business.
• The closing capital at ONCO provides non-dilutive financing to grow the commercial robotics and AI business.

"Once listed on the Nasdaq, there will be a clearer and more visible market value for the commercial robotics business and greater access to capital, institutional investors, and long-term growth opportunities," said Andrew Kiguel, chief executive officer of Realbotix. "Importantly, existing Realbotix shareholders will continue to participate in the future upside of the commercial robotics division through ownership in the Nasdaq-listed entity."

"Onconetix is committed to completing the acquisition of Realbotix LLC. Every day we read more about AI and the role humanoid robots will play in our future," said David White, CEO of Onconetix. "This transaction will give Onconetix an opportunity to participate in this rapidly developing part of the market."

RealLLC is a Nevada-based subsidiary of Realbotix, the parent company. RealLLC designs and manufactures AI-powered humanoid robots for use in consumer-facing social roles such as customer service, health care, education, hospitality and entertainment. RealLLC's operations include an engineering division, AI software division, robotics patents and intellectual property.

RealLLC is a leader in embodied and physical AI with technology that enables autonomous humanoid robot behaviour and does not require teleoperation from a human to function.

The proposed transaction, first announced on Feb. 12, 2026, remains subject to certain conditions precedent to closing, including the requisite approval of the ONCO shareholders and regulators.

About Realbotix Corp.

Realbotix is a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments.

Manufactured in the United States, Realbotix's patented AI and robotics technologies enable lifelike expressions, motion, agentic vision and social engagement, positioning Realbotix as a category leader in the rapidly evolving field of human-centric robotics and embedded-AI solutions.

About Onconetix Inc.

Onconetix (Nasdaq: ONCO) is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Onconetix owns Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (EU) under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test (LDT) through its license agreement with Labcorp.

We seek Safe Harbor.